title: Prevalence and determinants of cannabinoid prescription for the management of chronic noncancer pain: a postal survey of physicians in the Abitibi-Témiscamingue region of Quebec.
abstract: BACKGROUND
  Few studies have been conducted to explore physicians' prescription practices and attitudes toward the use of cannabinoids in Canada.We measured the prevalence and identified determinants of cannabinoid prescription for the management of chronic noncancer pain among physicians in southwestern Quebec.
  
  
  METHODS
  In February 2013, we conducted a postal survey using a modified Dillman method that involved physicians practising in the Abitibi-Témiscamingue region of Quebec. We used multivariate logistic regression models to identify determinants of cannabinoid prescription.
  
  
  RESULTS
  A total of 166 physicians of 318 practising in the region participated in the survey (response rate 52.2%). The prevalence of cannabinoid prescription was 27.3% (45/165) for any indication and 23.0% (38/165) for the management of chronic noncancer pain; 91.1% (41/45) of the physicians prescribed cannabinoids to 5 or fewer patients. Of the 38 physicians who prescribed cannabinoids for chronic noncancer pain, 35 (92.1%) prescribed nabilone, 7 (18.4%) medical marijuana and 2 (5.3%) nabiximols. The principal determinant of cannabinoid prescription was the physician's level of comfort with prescribing cannabinoids (adjusted odds ratio 1.25, 95% confidence interval 1.01-1.55, per 1-point increase in comfort level measured on 10-point scale). Respondents reported that continuing medical education (CME) activities could increase their comfort level. They also indicated a need for guidelines or algorithms that included cannabinoid use as well as more studies about the efficacy and safety of cannabinoids for the management of chronic noncancer pain.
  
  
  CONCLUSIONS
  We found that cannabinoids were not often prescribed for the management of chronic noncancer pain and that survey respondents were not comfortable with prescribing this drug class. This degree of discomfort could be addressed by CME activities, more effective dissemination of guidelines and more evidence regarding cannabinoid use for the management of chronic noncancer pain.
authors.affiliation: Département des sciences de la santé, Université du Québec en Abitibi-Témiscamingue, Rouyn-Noranda, Que.
authors.forename: Huguette
authors.initials: H
authors.lastname: St-Amant
authors.affiliation: Alan Edwards Pain Management Unit, McGill University Health Centre, Montréal, Que.
authors.forename: Mark A
authors.initials: MA
authors.lastname: Ware
authors.affiliation: Département des sciences de la santé, Université du Québec en Abitibi-Témiscamingue, Rouyn-Noranda, Que.
authors.forename: Nancy
authors.initials: N
authors.lastname: Julien
authors.affiliation: Département des sciences de la santé, Université du Québec en Abitibi-Témiscamingue, Rouyn-Noranda, Que.
authors.forename: Anaïs
authors.initials: A
authors.lastname: Lacasse